The most prevalent gene identified in melanoma is the mutation of the proto-oncogene BRAF, present in 41% to 56% of all melanomas.12 This mutated protein is implicated in different means of melanoma progression, including activation of the MEK/ERK pathway, evading the immune response, senescence, and apoptosis as well as angiogenesis, tissue invasion, and metastasis.13,14 In 2010, BRAF mutation was first described as a therapeutic target and currently is the standard of care for suitable patients.15,16. The gene discussed is BRAF; the disease is melanoma.